Group B streptococcal infection future or investigational therapies
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]
Overview
GBS vaccines have been investigated as a tool for reducing maternal colonization and preventing transmission to neonates;[1] however, no licensed vaccine is available currently. Phase I and II clinical trials among healthy, non-pregnant adults of monovalent polysaccharide-protein conjugate vaccines of GBS disease-associated types have shown these vaccines to be well tolerated and immunogenic.[2][3] A recent, double-blind randomized trial of a conjugate vaccine against GBS serotype III among non-pregnant women of reproductive age found a significant delay in acquisition of colonization with the vaccine-serotype among vaccine recipients.[4][5]
References
- ↑ Baker CJ, Rench MA, Edwards MS, Carpenter RJ, Hays BM, Kasper DL (1988). “Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus”. N Engl J Med. 319 (18): 1180–5. doi:10.1056/NEJM198811033191802. PMID 3050524.
- ↑ Baker CJ, Edwards MS (2003). “Group B streptococcal conjugate vaccines”. Arch Dis Child. 88 (5): 375–8. PMC 1719562. PMID 12716700.
- ↑ Baker CJ, Paoletti LC, Rench MA, Guttormsen HK, Carey VJ, Hickman ME; et al. (2000). “Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women”. J Infect Dis. 182 (4): 1129–38. doi:10.1086/315839. PMID 10979909.
- ↑ Hillier S, Ferris D, Fine D, Ferrieri P, et al. Women receiving group B Streptococcus serotype III tetanus toxoid (GBS III-TT) vaccine have reduced vaginal and rectal acquisition of GBS type III [Presentation]. Annual meeting of the Infectious Diseases Society of America, Philadelphia, Pennsylvania; October 20–November 1, 2009.
- ↑ Verani J.R., McGee L, and Schrag S.J. Prevention of Perinatal Group B Streptococcal Disease. Revised Guidelines from CDC, 2010.CDC.gov
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH